

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

To BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	To The National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. GopalKrishnan	Kind Attn.: Farmoze Pochara Asst. Vice President
Code: 532321	Code: CADILAHC
Date: January 05, 2016	
Reg.: Press Release titled – Zydus expands animal health business with a strategic acquisition	

Dear Sir / Madam,

We hereby pleased to announce that the Board of Directors at its meeting held on today approved the proposal to expand its animal health business with a strategic acquisition.

A detailed press release on acquisition is attached and is self-explanatory.

Please bring the aforesaid information to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
FOR CADILA HEALTHCARE LIMITED



UPEN H. SHAH
COMPANY SECRETARY

Encl. As above.

Zydus expands animal health business with a strategic acquisition

Acquires Zoetis' select brands and manufacturing operations in Haridwar, India

Ahmedabad, January 5, 2016

Zydus Group which is a leading player in the animal health business through its division Zydus Animal Health has announced the strategic acquisition of select brands and the manufacturing operations in Haridwar, India, of Zoetis a global animal health company. The acquisition will help Zydus expand its animal health business in India and gain access to manufacturing operations which have also been catering to global markets. The financial details of the deal remain undisclosed.

As a result of this acquisition, Zydus gains access to a wide range of nutrition as well as therapeutic products which have strong brand equity and a combined turnover of Rs. 171 Cr. A major boost to Zydus' portfolio would be the addition of livestock farmcare products which are well accepted in the market. Zydus' access to the WHO GMP approved manufacturing facility is expected to boost its exports and institutional business. The plant spread over 10,000 sq. metres manufactures Tablets, Liquid Orals and Injectables.

Speaking on the development, Chairman and Managing Director, Zydus Cadila, Mr. Pankaj R. Patel said, "We believe that this strategic acquisition will strengthen our portfolio of brands and add new dimensions to our growth in the animal health business. We see this as an opportunity to catapult our business to higher levels of excellence."

With a strong presence in the livestock and poultry segments, Zydus Animal Health is India's leading animal healthcare player and a market leader in various therapeutic segments which include antibacterials, NSAIDs, antimastitis, tonics and poultry vaccines amongst others in India. Zydus Animal Health has introduced the highest number of 'First in India' products, in keeping with its mission to provide innovative solutions that improve animal health and farm productivity.
